Several consensus documents from different scientific societies currently recommend the prescription of GLP1-RA and/or SGLT2i with proven CV and renal benefits in patients at high risk or with DKD, regardless of their HbA1c levels. This evidence concerns the gene GCG and diabetic kidney disease.